Format

Send to

Choose Destination
Clin J Oncol Nurs. 2006 Oct;10(5):559-60.

Gardasil: Introducing the new human papillomavirus vaccine.

Author information

1
Department of Physiologic Nursing, School of Nursing, University of California, San Francisco, USA. monica.mclemore@ucsf.edu

Abstract

In 2006, the U.S. Food and Drug Administration (FDA) approved the first vaccine for prevention of cervical cancer based on the molecular biology of the disease. Gardasil (quadrivalent human papillomavirus [HPV] [types 6, 11, 16, and 18] recombinant vaccine, Merck & Co., Inc., Whitehouse Station, NJ) combats the common types of HPV responsible for cervical cancer precursor lesions. This article provides a simple overview of the (a) epidemiology of HPV, (b) HPV vaccine, (c) dosing and administration, and (d) nursing implications about this possibly life-saving vaccine.

PMID:
17063609
DOI:
10.1188/06.CJON.559-560
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Oncology Nursing Society
Loading ...
Support Center